Free Trial

IGC Pharma (IGC) Stock Price, News & Analysis

+0.01 (+1.93%)
(As of 05/22/2024 ET)
Today's Range
50-Day Range
52-Week Range
223,893 shs
Average Volume
599,794 shs
Market Capitalization
$35.21 million
P/E Ratio
Dividend Yield
Price Target
IGC stock logo


IGC Pharma, Inc., a clinical stage biotechnology company, engages in developing cannabinoid-based formulations for treating diseases and conditions, including Alzheimer's disease, dysmenorrhea, premenstrual syndrome, and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease comprising IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63 that is in pre-clinical development. It also markets Holief, a wellness brand that targets women experiencing premenstrual syndrome and menstrual cramps. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.

IGC Stock Price History

IGC Stock News Headlines

IGC Pharma to Attend BIO International Convention 2024
IGC Pharma Inc.
IGC Pharma Adds Advisor in Artificial Intelligence
See More Headlines
Receive IGC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IGC Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$0.28 per share


Free Float
Market Cap
$35.21 million
Not Optionable
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Ram Mukunda (Age 65)
    President, CEO & Director
    Comp: $705k
  • Ms. Claudia Grimaldi (Age 53)
    VP, Principal Financial Officer, Chief Compliance Officer & Non-Independent Director
    Comp: $245k
  • Mr. Rohit Goel (Age 30)
    Senior Director of Accounting & Principal Accounting Officer

IGC Stock Analysis - Frequently Asked Questions

How have IGC shares performed in 2024?

IGC Pharma's stock was trading at $0.3446 at the start of the year. Since then, IGC shares have increased by 52.9% and is now trading at $0.5270.
View the best growth stocks for 2024 here

Are investors shorting IGC Pharma?

IGC Pharma saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 1,210,000 shares, an increase of 57.5% from the April 15th total of 768,100 shares. Based on an average trading volume of 968,400 shares, the short-interest ratio is currently 1.2 days.
View IGC Pharma's Short Interest

How were IGC Pharma's earnings last quarter?

IGC Pharma, Inc. (NYSEAMERICAN:IGC) issued its earnings results on Monday, February, 10th. The construction company reported ($0.04) earnings per share for the quarter. The construction company had revenue of $0.57 million for the quarter. IGC Pharma had a negative net margin of 1,163.24% and a negative trailing twelve-month return on equity of 110.37%.

What other stocks do shareholders of IGC Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IGC Pharma investors own include GW Pharmaceuticals (GWPH), Alibaba Group (BABA), Tilray (TLRY), Cronos Group (CRON), Micron Technology (MU), NewAge (NBEV), Advanced Micro Devices (AMD), Ford Motor (F) and NIO (NIO).

How do I buy shares of IGC Pharma?

Shares of IGC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:IGC) was last updated on 5/23/2024 by Staff

From Our Partners